Lexicon Pharmaceuticals Newsroom

Lexicon Pharmaceuticals Announced New Analysis Of Phase 3 SCORED Clinical Trial Demonstrating The Protective Effects Of Sotagliflozin In Patients With Diabetic Kidney Disease

BenzingaOct 23 21:03

New Analysis of Phase 3 Data Demonstrating Renal Protective Benefits of Sotagliflozin to Be Presented at ASN Kidney Week 2024

GlobeNewswireOct 23 21:00

Express News | Lexicon Pharmaceuticals Inc - Top-Line Data for Lx9211 Now Anticipated in Q1 2025

BreakingsOct 22 20:01

Express News | Lexicon Announces Completion of Screening in Phase 2B Progress Study of Lx9211 in Diabetic Peripheral Neuropathic Pain (Dpnp)

BreakingsOct 22 20:00

Lexicon Announces Completion of Screening in Phase 2B Progress Study of LX9211 in Diabetic Peripheral Neuropathic Pain (DPNP)

GlobeNewswireOct 22 20:00

Lexicon Pharmaceuticals: Strategic Advancements and Growth Potential Highlighted by Exclusive Licensing Deal and Undervalued Pipeline

TipRanksOct 21 20:25

Strategic Partnership and Financial Incentives Drive Buy Rating for Lexicon Pharmaceuticals

TipRanksOct 17 18:25 · Ratings

Express News | Lexicon Pharmaceuticals Inc - May Get From Viatris up to $185 Mln Upon Achievement of Specified Sales Milestones Under License Deal

BreakingsOct 17 04:39

Express News | Viatris Inc - to Pay $25 Million Upfront for Sotagliflozin Rights

BreakingsOct 17 04:35

Lexicon Announces Exclusive Licensing Agreement With Viatris for Sotagliflozin in All Markets Outside of the U.S. and Europe

GlobeNewswireOct 17 04:35

Express News | Viatris Announces Exclusive Licensing Agreement With Lexicon Pharmaceuticals for Sotagliflozin in All Markets Outside of the U.S. and Europe

BreakingsOct 17 04:34

Press Release: Viatris Announces Exclusive Licensing Agreement With Lexicon Pharmaceuticals for Sotagliflozin in All Markets Outside of the U.S. and Europe

Dow JonesOct 17 04:34

Piper Sandler Maintains Lexicon Pharmaceuticals(LXRX.US) With Buy Rating, Maintains Target Price $10

Futu NewsOct 10 18:31 · Ratings

Lexicon Pharmaceuticals Inc (LXRX) Q2 2024 Earnings Call Highlights: Strategic Advancements ...

InvestingOct 9 21:53

Q3 Pharma and Biotech Layoffs in Charts: More Than 1000 Each in July and August

Seeking AlphaOct 5 02:02

Buy Rating Affirmed for Lexicon Pharmaceuticals Based on Sotagliflozin's Market Potential and Favorable Safety Data

TipRanksOct 3 18:17 · Ratings

Beyond The Numbers: 7 Analysts Discuss Lexicon Pharmaceuticals Stock

BenzingaSep 28 01:01

H.C. Wainwright Maintains Lexicon Pharmaceuticals(LXRX.US) With Buy Rating, Maintains Target Price $10

Futu NewsSep 27 23:32 · Ratings

HC Wainwright & Co. Reiterates Buy on Lexicon Pharmaceuticals, Maintains $10 Price Target

BenzingaSep 27 23:22 · Ratings

Lexicon Pharmaceuticals Analyst Ratings

BenzingaSep 27 23:20 · Ratings